Corridor Pharmaceuticals, Inc.

Pioneering the development and commercialization of therapeutic inhibitors to combat hyperplasia and fibrosis through innovative small molecule therapies.

General Information
Company Name
Corridor Pharmaceuticals, Inc.
Founded Year
2007
Location (Offices)
+1
Founders / Decision Makers
Number of Employees
2-10
Industries
Biotechnology, Health Care, Health and Wellness
Funding Stage
Debt Financing
Social Media

Corridor Pharmaceuticals, Inc. - Company Profile

Corridor Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on developing and commercializing therapeutic small molecule inhibitors of arginase, an enzyme that competes with endothelial nitric oxide synthase for l-arginine, a common substrate. The company's arginase also produces ornithine, which elevates polyamine levels, stimulates cell division, and contributes to hyperplasia and fibrosis. Founded in 2007 and based in Lutherville, Maryland, the company was originally known as Arginetix, Inc., before changing its name to Corridor Pharmaceuticals, Inc. on June 17, 2010. Corridor Pharmaceuticals, Inc. is pioneering the development and commercialization of therapeutic inhibitors to combat hyperplasia and fibrosis through innovative small molecule therapies. The company has received a $1.56M Debt Financing investment on January 31, 2013, demonstrating interest and confidence from the investment community in its potential to make significant strides in the biotechnology and healthcare industries.

Taxonomy: Biopharmaceutical, Therapeutic Inhibitors, Small Molecule Therapies, Arginase Inhibitors, Hyperplasia Treatment, Fibrosis Treatment, Enzyme Inhibition, Polyamine Modulation, Cell Division, Biomedical Innovation, L-Arginine Metabolism, Drug Development, Healthcare Research, Biotech Startups, Medical Therapies

Funding Rounds & Investors of Corridor Pharmaceuticals, Inc. (4)

View All
Funding Stage Amount No. Investors Investors Date
Debt Financing $1.56M - 31 Jan 2013
Series A $13.01M 9 Acidophil, Maryland Health Care Product Development +2 24 Jun 2010
Series A $10.75M 1 OUP (Osage University Partners) 02 Oct 2009
Seed Round $2.30M - 23 Oct 2008

Latest News of Corridor Pharmaceuticals, Inc.

View All

No recent news or press coverage available for Corridor Pharmaceuticals, Inc..

Similar Companies to Corridor Pharmaceuticals, Inc.

View All
Idenix Pharmaceuticals - Similar company to Corridor Pharmaceuticals, Inc.
Idenix Pharmaceuticals Pioneering advancements in antiviral therapies, focused on combating hepatitis and HIV, with a strong presence in the U.S. and Europe.
Kiora Pharmaceuticals, Inc. - Similar company to Corridor Pharmaceuticals, Inc.
Kiora Pharmaceuticals, Inc. Developing advanced therapies for retinal disease
DAAN Biotherapeutics - Similar company to Corridor Pharmaceuticals, Inc.
DAAN Biotherapeutics Innovative treatments for cancer: empowering patients with advanced research in cell therapies, antibodies, and small molecule inhibitors.
Arriva Pharmaceuticals - Similar company to Corridor Pharmaceuticals, Inc.
Arriva Pharmaceuticals Pioneering the future of healthcare with innovative protease inhibitors for diverse therapeutic needs
Actuate Therapeutics, Inc. - Similar company to Corridor Pharmaceuticals, Inc.
Actuate Therapeutics, Inc. Pioneering advancements in the fight against high-impact cancers and neurodegenerative diseases with groundbreaking compounds targeting GSK-3β.